The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.
April 19th 2024
The current health care economy has driven many employers to self-funding models to offer affordable health care coverage to employees.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Pazdur Followed the Pathway of Greatest Resistance to the FDA
Richard Pazdur, MD, set out to be a leader in medicine and a teacher of doctors. He achieved that and more, turning the oncology drugs section of the FDA from a poorly understood and lead-footed division into a fast-moving and patient-responsive entity.
Healthcare "Hot-Spotting" Generates Big Savings in Oncology
Focusing on the needs of patients with cancer who were likely to be “superutilizers” of healthcare resources resulted in lower costs, fewer hospital admissions, and higher patient satisfaction scores for Crystal Run Healthcare.
OCM Participants Consider Costs of 2-Sided Risk
November 25th 2019After 3 years of struggling to meet targets for improved care quality and cost efficiency, many of the 175 practices that have remained in the Oncology Care Model of the Centers for Medicare & Medicaid Services have a decision to make: Assume a share of the downside risk for failure to meet financial targets or exit the OCM by December 3.
A Society That Worries About Risks Should Consider Cancer Prevention
November 23rd 2019When discussing the topic of vaccination to prevent serious childhood illness, an increasing number of individuals refuse to accept the unequivocally demonstrated value of this public health strategy despite the very low risk of harm.
The ACCC David King Community Clinical Scientist Award was awarded to Paul D. Hansen, MD, FACS, a pioneering leader in research on minimally invasive approaches to major liver and pancreas surgery and the promise these techniques hold for improving the quality of care, the patient experience, and potentially reducing healthcare costs.
Can New Oncology Payment Programs Help Stabilize Medicare?
October 30th 2019Studies have raised doubts about the value Medicare and other payers are getting for the care they pay for, including in oncology. This has intensified the demand for new value-based care models such as the Merit-based Incentive Payment System and the Oncology Care Model.
Innovative Center Focuses on Phase I Trials
October 15th 2019A partnership between a healthcare system in Morristown, New Jersey, and a genomics research institute in Phoenix, Arizona, has led to the opening of a center dedicated to offering phase I cancer trials in community settings and improving access for patients with limited coverage.
End-of-Life Treatment Has Important Nuances
October 13th 2019Even if a disease is diagnosed as “incurable,” or progression to a state of incurability subsequently develops, the time between diagnosis and death is being prolonged and the quality of life improved with novel oncologic interventions, such that continued therapeutic efforts are justified.
New ASCO System Confronts Lack of EHR Interoperability
October 3rd 2019With the recent launch of a free, open-source system for standardizing the electronic storage of patient records, the American Society of Clinical Oncology hopes to improve information flow across electronic health record platforms and curtail the harms of information blocking by private aggregators and vendors of patient information.
CFS® Experts: Novel Therapies and Onco-Genomics Add Heft to Precision Medicine
Co-chairs William K. Oh, MD, Adam M. Brufsky, MD, PhD, and Benjamin P. Levy, MD, preview key topics that will be covered at the 37th Annual CFS®: Innovative Cancer Therapy for Tomorrow symposium.
Medical Partners Open Phase I Trial Center to Improve Access, Novel Drug Development
September 27th 2019Atlantic Health System of Morristown New Jersey and Translational Genomics Research Institute of Arizona have opened a center dedicated to phase I clinical trials in cancer and improving access for patients with limited coverage.
Therapeutic Vaccines Lead the Charge in HPV-Driven Cancers
September 24th 2019The development of therapeutic vaccines for patients with cancers associated with the human papillomavirus has emerged as a leading strategy in continuing research efforts to address the growing public health threat posed by the virus.
Small Subgroups May Hold Big Clinical Clues in Oncology
September 23rd 2019With the revolution in our understanding of cancer’s basic molecular biology, it is increasingly evident that subgroups of cancer originating from specific regions of the body have unique natural histories and respond to very different therapeutics. For example, the importance of BRCA mutations, which define a subset of ovarian cancers impressively sensitive to PARP inhibitors, has striking altered the management of this group of gynecologic malignancies.
The FDA Could Help Address Financial Toxicity During the Approval Process
September 21st 2019Given the widespread financial impact the high cost of cancer drugs has on the healthcare system, it may be time for the FDA to take a broader approach when reviewing oncology drug applications. By also examining the cost of the drug, the FDA could shine a light on escalating drug costs and play a leadership role in creating new programs and initiatives that help patients pay for promising new therapies.